Ryan Marsh

Newcastle Upon Tyne, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 8 publications

Towards a gut-lung axis role in pwCF on CFTR modulators: rationale, clinical evidence and perspectives.

Towards a gut-lung axis role in pwCF on CFTR modulators: rationale, clinical evidence and perspectives.

Journal: Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society

Published: November 14, 2025

The gut microbiome: Recent findings and future opportunities in cystic fibrosis.

The gut microbiome: Recent findings and future opportunities in cystic fibrosis.

Journal: Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society

Published: November 13, 2025

Remodelling of cystic fibrosis respiratory microbiota in response to extended elexacaftor-tezacaftor-ivacaftor therapy.

Remodelling of cystic fibrosis respiratory microbiota in response to extended elexacaftor-tezacaftor-ivacaftor therapy.

Journal: Microbiome

Published: September 26, 2025

Investigating microbiota differences across chronic pancreatitis, influenced by lifestyle and genetic determinants.

Investigating microbiota differences across chronic pancreatitis, influenced by lifestyle and genetic determinants.

Journal: BMC gastroenterology

Published: January 30, 2025

Species turnover within cystic fibrosis lung microbiota is indicative of acute pulmonary exacerbation onset.

Species turnover within cystic fibrosis lung microbiota is indicative of acute pulmonary exacerbation onset.

Journal: Microbiome

Published: October 31, 2024

Impact of extended Elexacaftor/Tezacaftor/Ivacaftor therapy on the gut microbiome in cystic fibrosis.

Impact of extended Elexacaftor/Tezacaftor/Ivacaftor therapy on the gut microbiome in cystic fibrosis.

Journal: Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society

Published: January 22, 2024

Tezacaftor/Ivacaftor therapy has negligible effects on the cystic fibrosis gut microbiome.

Tezacaftor/Ivacaftor therapy has negligible effects on the cystic fibrosis gut microbiome.

Journal: Microbiology spectrum

Published: August 22, 2023

Intestinal function and transit associate with gut microbiota dysbiosis in cystic fibrosis.

Intestinal function and transit associate with gut microbiota dysbiosis in cystic fibrosis.

Journal: Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society

Published: August 11, 2021

Showing 1-8 of 8

Last Updated: 09/26/2026